Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Issue 5 (13th January 2022)

• Record Type: Journal Article
• Authors: Bonelli, Michael; Mrak, Daniel; Tobudic, Selma; Sieghart, Daniela; Koblischke, Maximilian; Mandl, Peter; Kornek, Barbara; Simader, Elisabeth; Radner, Helga; Perkmann, Thomas; Haslacher, Helmuth; Mayer, Margareta; Hofer, Philipp; Redlich, Kurt; Husar-Memmer, Emma; Fritsch-Stork, Ruth; Thalhammer, Renate; Stiasny, Karin; Winkler, Stefan; Smolen, Josef S; Aberle, Judith H; Zeitlinger, Markus; Heinz, Leonhard X; Aletaha, Daniel
• Is Part Of: Annals of the rheumatic diseases. Volume 81:Issue 5(2022)
• Page Start: 687
• Page End: 694
• Publication Date: 2022-01-13
• Subjects: rituximab -- vaccination -- Covid-19; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2021-221558
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: SARS‐CoV‐2-induced COVID-19 has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to conventional COVID-19 vaccination. Methods: In this blinded randomised clinical trial, we compare the efficacy and safety of an additional booster vaccination with a vector versus mRNA vaccine in non-seroconverted patients. We assigned 60 patients under rituximab treatment, who did not seroconvert after their primary mRNA vaccination with either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna), to receive a third dose, either using the same mRNA or the vector vaccine ChAdOx1 nCoV-19 (Oxford–AstraZeneca). Patients were stratified according to the presence of peripheral B cells. The primary efficacy endpoint was the difference in the SARS-CoV-2 antibody seroconversion rate between vector (heterologous) and mRNA (homologous) vaccinated patients by week 4. Key secondary endpoints included the overall seroconversion and cellular immune response; safety was assessed at week 1 and week 4. Results: Seroconversion rates at week 4 were comparable between vector (6/27 patients, 22%) and mRNA (9/28, 32%) vaccines (p=0.6). Overall, 27% of patients seroconverted; specific T cell responses were observed in 20/20 (100%) vector versus 13/16 (81%) mRNA vaccinated patients. Newly induced humoral and/or cellular responses occurred in 9/11 (82%) patients. 3/37 (8%) of patients without and 12/18 (67%) of the patients with detectable peripheral B cells seroconverted. No serious adverse events, related to immunisation, were observed. Conclusions: This enhanced humoral and/or cellular immune response supports an additional booster vaccination in non-seroconverted patients irrespective of a heterologous or homologous vaccination regimen.